NCT01667471View on ClinicalTrials.gov

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg iv every 4 weeks, 104 weeks

Trial Locations (3)

28177

Bremen

53757

Sankt Augustin

60316

Frankfurt am Main

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01667471 - A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study | Biotech Hunter | Biotech Hunter